Then, after ligation of the linker-drug derivative 54, based on the monomethyl auristatin E (3), with the reduced anti-CD30 chimeric immunoglobulin G subclass cAC10 mAb, furnished ADC 55, whose characterization led to a stable and homogeneous DAR distribution of 4, and excellent stability in the presence of thiol-containing proteins, such as human serum albumin (HSA), and a similar efficacy profile to Adcetris in a Karpas 299 xenograft model of CD30-positive lymphoma, with complete tumor regression in all mice when treated once at 1 mg/kg of 55 [112]. Here, TNFRSF8 is linked to neoplasm.